Invest in Ventoux Biosciences: Transforming the $4B Dupuytren's Disease Market with Novel Treatment

1

Dupuytren's impacts >40m patients in US and Europe and global disease market size est. at USD $4.3B

2

Completed in vivo mouse study, achieved anti-fibrotic effects with lead candidate (VEN-201)

3

Advancing lead candidate (VEN-201) to initial FDA meeting and formulation optimization

4

Currently, no approved pharmacologic treatment options to slow / delay progression of Dupuytren's

5

Surgery remains the treatment standard however, has high disease recurrence & post-op complications

6

Founded by a Dupuytren's patient to advance treatment for fellow patients and future generations

7

Guided by world class scientific advisory board of Dupuytren's and fibrosis experts

8

Awarded 2023 Biopharmaceutical Company of the Year and 2023 Chronic Inflammatory Company of the Year

Invest in Ventoux Biosciences